Intestinal lipid transport and chylomicron production: Possible links to exacerbated atherogenesis in a rodent model of the metabolic syndrome

Atherosclerosis Supplements

Volumn 9, Issue 2, 2008, Pages 69-76

  Vine, Donna F ^a   Glimm, David R ^a   Proctor, Spencer D ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Arterial proteoglycan; Atherosclerosis; Cardiovascular disease; Chylomicron; Chylomicron remnant; Insulin resistance; Intestinal lipid metabolism; Intestinal lipid transport; Metabolic syndrome; Obesity; Post prandial lipaemia

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN B48; CHOLESTEROL; CHYLOMICRON; GLYCOSAMINOGLYCAN; LIPOPROTEIN;

ARTERY; ATHEROGENESIS; CARDIOVASCULAR DISEASE; DISEASE COURSE; DYSLIPIDEMIA; FAT INTAKE; HYPERLIPIDEMIA; INSULIN RESISTANCE; INTESTINE; INTESTINE VILLUS; LIPID METABOLISM; LIPID STORAGE; LIPID TRANSPORT; LIPOGENESIS; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; POSTPRANDIAL STATE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RODENT;

ANIMALS; ATHEROSCLEROSIS; CHYLOMICRONS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; INTESTINAL ABSORPTION; INTESTINES; LIPID METABOLISM; METABOLIC SYNDROME X; RODENTIA;

EID: 50449089236     PISSN: 15675688     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosissup.2008.05.004     Document Type: Review

References (72)

1. Caballero A.E. Metabolic and vascular abnormalities in subjects at risk for type 2 diabetes: the early start of a dangerous situation. Arch Med Res 36 (2005) 241-249
2. Eckel R.H., Grundy S.M., and Zimmet P. The metabolic syndrome. Lancet 365 (2005) 1415-1428
3. Williams K.J., and Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 15 5 (1995) 551-561
4. Steinberg D. The pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy. Part III. Mechanistically defining the role of hyperlipidemia in the pathogenesis. J Lipid Res 46 10 (2005) 2037-2051
5. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 2002;359:1379-87.
6. Mediene-Benchekor S., et al. Blood lipid concentrations and risk of myocardial infarction. Lancet 358 (2001) 1064-1065
7. Colhoun H.M., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multi-centre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
8. Zilversmit D.B. Atherogenic nature of triglycerides, postprandial lipidemia and triglyceride rich remnant lipoproteins. Clin Chem 41 (1995) 153-158
9. Cabezas M.C., and Erkelens D.W. Triglycerides and atherosclerosis: to feast or fast. Neth J Med 56 (2000) 110-118
10. Proctor S.D., and Mamo J.C.L. Arterial retention of apolipoprotein B48 and B100-containing lipoproteins in atherogenesis. Curr Opin Lipidol 13 (2002) 461-470
11. Huff M.W. Dietary cholesterol, cholesterol absorption, postprandial lipemia and atherosclerosis. Can J Clin Pharmacol 10 Suppl A (2003) 26A-32A
12. Karpe F., Steiner G., Uffelman K., Olivecrona T., and Hamsten A. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis 106 1 (1994) 83-97
13. Twickler T., Dallinga-Thie G.M., Chapman M.J., and Cohn J.S. Remnant lipoproteins and atherosclerosis. Curr Atheroscler Rep 7 (2005) 140-147
14. Proctor S.D., Vine D.F., and Mamo J.C.L. Arterial retention of apolipoprotein-B48 and B100-containing lipoproteins in atherogenesis. Curr Opin Lipidol 13 (2002) 461-470
15. Nzekwu M.M., Ball G.D., Jetha M.M., Beaulieu C., and Proctor S.D. Apolipoprotein B48: a novel marker of metabolic risk in overweight children?. Biochem Soc Trans 35 Pt 3 (2007) 484-486
16. Mamo J.C.L., and Proctor S.D. Chylomicron remnants and atherosclerosis. In: Barter P.J., and Rye K.-A. (Eds). Plasma lipids and their role in disease (1999), Harwood Academic Publishers 109-137 [Chapter 6]
17. Proctor S.D., Vine D.F., and Mamo J.C. Arterial permeability and efflux of apolipoprotein B-containing lipoproteins assessed by in situ perfusion and three-dimensional quantitative confocal microscopy. Arterioscler Thromb Vasc Biol 24 (2004) 2162-2167
18. Proctor S.D., and Mamo J.C. Intimal retention of cholesterol derived from apolipoprotein B100- and apolipoprotein B48-containing lipoproteins in carotid arteries of Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb Vasc Biol 23 (2003) 1595-1600
19. Proctor S.D., and Mamo J.C.L. Retention of fluorescent labelled chylomicron-remnants within the intima of the arterial wall-evidence that plaque cholesterol may be derived from postprandial lipoproteins. Eur J Clin Invest 28 (1998) 497-503
20. Cabezas M.C., de Bruin T.W., Westerveld H.E., Meijer E., and Erkelens D.W. Delayed chylomicron remnant clearance in subjects with heterozygous familial hypercholesterolemia. J Intern Med 244 (1998) 299-307
21. Dane-Stewart C.A., Watts G.F., Pal S., et al. Effect of atorvastatin on apolipoprotein B48 metabolism and low-density lipoprotein receptor activity in normolipidemic patients with coronary artery disease. Metabolism 52 (2003) 1279-1286
22. Dane-Stewart C.A., Watts G.F., Mamo J.C., et al. Elevated apolipoprotein B-48 and remnant-like particle-cholesterol in heterozygous familial hypercholesterolemia. Eur J Clin Invest 31 (2001) 113-117
23. Schaefer E.J., et al. Elevated remnant-like particle cholesterol and triglyceride levels in diabetic men and women in the Framingham Offspring Study. Diabetes Care 25 (2002) 989-994
24. Chan D.C., Watts G.F., Barrett P.H., et al. Relationships between cholesterol homoeostasis and triacylglycerol-rich lipoprotein remnant metabolism in the metabolic syndrome. Clin Sci (Lond) 104 (2003) 383-388
25. Mamo J.C., Watts G.F., Barrett P.H., et al. Postprandial dyslipidemia in men with visceral obesity: an effect of reduced LDL receptor expression?. Am J Physiol Endocrinol Metab 281 (2001) E626-E632
26. Chan D.C., Watts G.F., Barrett P.H., et al. Effect of atorvastatin on chylomicron remnant metabolism in visceral obesity: a study employing a new stable isotope breath test. J Lipid Res 43 (2002) 706-712
27. Mekki N., Christofilis M.A., Charbonnier M., et al. Influence of obesity and body fat distribution on postprandial lipemia and triglyceride-rich lipoproteins in adult women. J Clin Endocrinol Metab 84 (1999) 184-191
28. Despres J.P., and Marette A. Relation of components of insulin resistance syndrome to coronary disease risk. Curr Opin Lipidol 5 (1994) 274-289
29. Kruit J.K., Groen A.K., van Berkel T.J., and Kuipers F. Emerging roles of the intestine in control of cholesterol metabolism. World J Gastroenterol 12 (2006) 6429-6439
30. Lally S., Owens D., and Tomkin G.H. Genes that affect cholesterol synthesis, cholesterol absorption, and chylomicron assembly: the relationship between the liver and intestine in control and streptozotosin diabetic rats. Metabolism 56 (2007) 430-438
31. Lewis G.F., Naples M., Uffelman K., et al. Intestinal lipoprotein production is stimulated by an acute elevation of plasma free fatty acids in the fasting states. Endocrinology 145 (2004) 5006-5012
32. Bonen A., Chabowski A., Luiken J.J., and Glatz J.F. Is membrane transport of FFA mediated by lipid, protein, or both? Mechanisms and regulation of protein-mediated cellular fatty acid uptake: molecular, biochemical and physiological evidence. Physiology (Bethesda) 22 (2007) 15-29
33. Drover V.A., Ajmal M., Nassir F., et al. CD36 deficiency impairs lipid clearance and clearance of chylomicrons from the blood. J Clin Invest 115 (2005) 1290-1297
34. Lally S., Tan C.Y., Owens D., and Tomkin G.H. Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: the role of Niemann-Pick C1-like 1, ATP-binding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein. Diabetologia 49 (2006) 1008-1016
35. Drozdowski L., Clement L., Keelan M., et al. Dietary lipids modify intestinal lipid-binding protein RNA abundance in diabetic and control rats. Digestion 70 (2004) 192-198
36. Nassir F., Wilson B., Han X., Gross R.W., and Abumrad N.A. CD36 is important for fatty acid and cholesterol uptake by the proximal but not distal intestine. J Biol Chem 282 (2007) 19493-19501
37. Nauli A.M., Nassir F., Zheng S., et al. CD36 is important for chylomicron formation and secretion and may mediate cholesterol uptake in the proximal intestine. Gastroenterology 131 (2006) 1197-1207
38. Hui D.Y., Labonte E.D., and Howles P.N. Development and physiological regulation of intestinal lipid absorption. III. Intestinal transporters and cholesterol absorption. Am J Physiol Gastrointest Liver Physiol (2008) February 14 [Epub ahead of print]
39. Federico L.M., Naples M., Taylor D., and Adeli K. Intestinal insulin resistance and aberrant production of apolipoprotein B48 lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia. Diabetes 55 (2006) 1316-1326
40. Mangat R., Su J., Scott P.G., et al. Chylomicron and apoB48 metabolism in the JCR:LA corpulent rat, a model for the metabolic syndrome. Biochem Soc Trans 35 Pt 3 (2007) 477-481
41. Chen M., Yang Y.K., Loux T.J., Georgeson K.E., and Harmon C.M. The role of hyperglycemia in FAT/CD36 expression and function. Pediatr Surg Int 22 (2006) 647-654
42. Haidari M., Leung N., Mahbub F., et al. Fasting and postprandial overproduction of intestinally derived lipoproteins in an animal model of insulin resistance. Evidence that chronic fructose feeding in the hamster is accompanied by enhanced intestinal de novo lipogenesis and ApoB48-containing lipoprotein overproduction. J Biol Chem 277 (2002) 31646-31655
43. Vine D.F., Takechi R., Russell J.C., and Proctor S.D. Impaired postprandial apolipoprotein-B48 metabolism in the obese, insulin-resistant JCR:LA-cp rat: increased atherogenicity for the metabolic syndrome. Atherosclerosis 190 (2007) 282-290
44. Hassanali Z., England A., O'Neill D., et al. Intestinal villi hypertrophy is associated with over-production of intestinal chylomicrons during conditions of obesity and hyperinsulinemia in the JCR:LA-cp rodent. Canadian lipoprotein conference. Quebec, October (2007)
45. Sukhotnik I., Gork A.S., Chen M., et al. Effect of low fat diet on lipid absorption and fatty-acid transport following bowel resection. Pediatr Surg Int 17 (2001) 259-264
46. Poirier H., Niot I., Degrace P., et al. Fatty acid regulation of fatty acid-binding protein expression in the small intestine. Am J Physiol 273 (1997) G289-G295
47. Chen M., Yang Y., Braunstein E., Georgeson K.E., and Harmon C.M. Gut expression and regulation of FAT/CD36: possible role in fatty acid transport in rat enterocytes. Am J Physiol Endocrinol Metab 281 (2001) E916-E923
48. Mathur S.N., Watt K.R., and Field F.J. Regulation of intestinal NPC1L1 expression by dietary fish oil and docosahexaenoic acid. J Lipid Res 48 (2007) 395-404
49. Martins I.J., and Redgrave T.G. Obesity and post-prandial lipid metabolism. Feast or famine?. J Nutr Biochem 15 (2004) 130-141
50. Martins I.J., Sainsbury A.J., Mamo J.C., and Redgrave T.G. Lipid and apolipoprotein B48 transport in mesenteric lymph and the effect of hyperphagia on the clearance of chylomicron-like emulsions in insulin-deficient rats. Diabetologia 37 (1994) 238-246
51. Karpe F., Bel M., Bjorkegren J., and Hamsten A. Quantification of post-prandial triglyceride-rich lipoproteins in healthy men by retinyl ester labeling and simultaneous measurements of apolipoproteins B-48 and B-100. Arterioscler Thromb Vasc Biol 15 (1995) 199-207
52. Feingold K.R., Lear S.R., and Moser A.H. De novo cholesterol synthesis in three different animal models of diabetes. Diabetologia 26 (1984) 234-239
53. Young N.L., Saudek C.D., Walters L., Lapeyrolerie J., and Chang V. Pre-venting hyperphagia normalizes 3-hydroxy-3methylglutaryl-CoA reductase activity in small intestine and liver of diabetic rats. J Lipid Res 23 (1982) 831-838
54. Lewis G.F., Uffelman K., Naples M., et al. Intestinal lipoprotein overproduction, a newly recognized component of insulin resistance, is ameliorated by the insulin sensitizer rosiglitazone: studies in the fructose-fed Syrian golden hamster. Endocrinology 146 (2005) 247-255
55. Duez H., Lamarche B., Valero R., et al. Both intestinal and hepatic lipoprotein production are stimulated by an acute elevation of plasma free fatty acids in humans. Circulation 117 18 (2008) 2369-2376
56. Duez H., Lamarche B., Uffelman K.D., et al. Hyperinsulinemia is associated with increased production rate of intestinal apolipoprotein B-48-containing lipoproteins in humans. Arterioscler Thromb Vasc Biol 26 (2006) 1357-1363
57. Tomkin G.H., and Owens D. Abnormalities in apo B-containing lipoproteins in diabetes and atherosclerosis. Diabetes Metab Res Rev 17 (2001) 27-43
58. Camejo G., Olsson U., Hurt-Camejo E., Baharamian N., and Bondjers G. The extracellular matrix on atherogenesis and diabetes-associated vascular disease. Atheroscler Suppl 3 (2002) 3-9
59. Raines E.W., and Ferri N. The immune system and atherogenesis. Cytokines affecting endothelial and smooth muscle cells in vascular disease. J Lipid Res 46 (2005) 1081-1092
60. Tannock L.R., Little P.J., Wight T.N., and Chait A. Arterial smooth muscle cell proteoglycans synthesized in the presence of glucosamine demonstrate reduced binding to LDL. J Lipid Res 43 (2002) 149-157
61. Little P.J., Tannock L., Olin K.L., Chait A., and Wight T.N. Proteoglycans synthesized by arterial smooth muscle cells in the presence of transforming growth factor-beta1 exhibit increased binding to LDLs. Arterioscler Thromb Vasc Biol 22 (2002) 55-60
62. Pandey M., Loskutoff D.J., and Samad F. Molecular mechanisms of tumor necrosis factor-alpha-mediated plasminogen activator inhibitor-1 expression in adipocytes. FASEB J 19 (2005) 1317-1319
63. Bauer B.S., Ghahary A., Scott P.G., et al. The JCR:LA-cp rat: a novel model for impaired wound healing. Wound Repair Regen 12 (2004) 86-92
64. Russell J.C., and Proctor S.D. Macro- and micro-vascular disease in a pre-diabetic animal model: the JCR:LA-cp rat. In: Hansen B.C., and Bray G. (Eds). The metabolic syndrome (2008), Humana Press
65. Camejo G., Hurt-Camejo E., Wiklund O., and Bondjers G. Association of apoB lipoproteins with arterial proteoglycans: Pathological significance and molecular basis. Atherosclerosis 139 (1998) 205-222
66. Olsson U., Ostergren-Lunden G., and Moses J. Glycosaminoglycan-lipoprotein interaction. Glycoconj J 18 (2001) 789-797
67. O'Brien K.D., Olin K.L., Alpers C.E., et al. Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: colocalization of biglycan with apolipoproteins. Circulation 98 (1998) 519-527
68. Skalen K., Gustafsson M., Rydberg E.K., et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 13 417 (2002) 750-754
69. Flood C., Gustafsson M., Pitas R.E., et al. Molecular mechanism for changes in proteoglycan binding on compositional changes of the core and the surface of low-density lipoprotein-containing human apolipoprotein B100. Arterioscler Thromb Vasc Biol 24 (2004) 564-570
70. Flood C., Gustafsson M., Richardson P.E., et al. Identification of the proteoglycan binding site in apolipoprotein B48. J Biol Chem 30 277 (2002) 32228-32233
71. Proctor S.D., Forbes J.M., and Mamo J.C.L. Accumulation of intestinal cholesterol-rich remnant lipoproteins within arterial vessels may be exacerbated by advanced glycation endproducts and the co-localisation of proteoglycans in diabetes. Proceedings abstract for XIII international symposium of atherosclerosis. IAS Kyoto, Japan, October (2003) [Atherosclerosis 4(2 Suppl):54 1p-0156]
72. Proctor S.D., Forbes J.M., and Mamo J.C.L. Accumulation of intestinal cholesterol-rich remnant lipoproteins within arterial vessels may be exacerbated by advanced glycation endproducts and the co-localisation of proteoglycans in diabetes. XIIIth International Symposium on Atherosclerosis, September 28-October 2. Kyoto, Japan (2003) [Atherosclerosis 4(2 Suppl):54 1p-0156]